Peroxisome proliferator-activated receptor gamma (
PPARgamma), a member of the
nuclear receptor superfamily, plays a role in adipocyte differentiation, type II diabetes, macrophage response to
inflammation and is suggested to influence
carcinogen-induced
colon cancer. Studies done in vitro and in vivo also revealed that
PPARgamma ligands might promote differentiation and/or regression of mammary
tumors. To directly evaluate the role of
PPARgamma in mammary
carcinogenesis,
PPARgamma wild-type (+/+) or heterozygous (+/-) mice were administered 1 mg 7,12-dimethylbenz[a]
anthracene (DMBA) by gavage once a week for 6 weeks and followed for a total of 25 weeks. Compared with congenic
PPARgamma(+/+) littermate controls,
PPARgamma(+/-) mice had early evidence for increased susceptibility to DMBA-mediated
carcinogenesis based on a 1.6-fold increase in the percentage of mice with skin
papillomas, as well as a 1.7-fold increase in the numbers of skin
papillomas per mouse (P < 0.05). Similarly,
PPARgamma(+/-) mice also had a 1.5-fold decreased survival rate (P = 0.059), and a 1.7-fold increased incidence of total
tumors per mouse (P < 0.01). Moreover,
PPARgamma(+/-) mice had an almost 3-fold increase in mammary
adenocarcinomas (P < 0.05), an over 3-fold increase in ovarian granulosa cell
carcinomas (P < 0.05), an over 3-fold increase in malignant
tumors (P < 0.02) and a 4.6-fold increase in metastatic incidence. These results are the first to demonstrate an increased susceptibility in vivo of
PPARgamma haploinsufficiency to DMBA-mediated
carcinogenesis and suggest that
PPARgamma may act as a
tumor modifier of skin, ovarian and breast
cancers. The data also support evidence suggesting a beneficial role for
PPARgamma-specific
ligands in the
chemoprevention of mammary, ovarian and skin
carcinogenesis.